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Abstract
 
The tumor necrosis factor (TNF) family member B cell activating factor (BAFF) binds B cells
and enhances B cell receptor–triggered proliferation. We find that B cell maturation antigen
(BCMA), a predicted member of the TNF receptor family expressed primarily in mature B
cells, is a receptor for BAFF. Although BCMA was previously localized to the Golgi apparatus,
BCMA was found to be expressed on the surface of transfected cells and tonsillar B cells. A sol-
uble form of BCMA, which inhibited the binding of BAFF to a B cell line, induced a dramatic
decrease in the number of peripheral B cells when administered in vivo. Moreover, culturing
splenic cells in the presence of BAFF increased survival of a percentage of the B cells. These re-
sults are consistent with a role for BAFF in maintaining homeostasis of the B cell population.
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Introduction
 
Many members of the TNF family fulfill important roles
related to the organization, function, and/or homeostasis of
the immune system (1). The recently identified TNF fam-
ily member B cell activating factor (BAFF) (TNF and apop-
tosis ligand–related leukocyte-expressed ligand 1 [TALL-
1]/TNF homologue that activates apoptosis, nuclear factor
 
k
 
B, and c-Jun NH
 
2
 
-terminal kinase [THANK]/B lympho-
cyte stimulator [BlyS]; references 2–5) is expressed in
monocytes, macrophages, and dendritic cells (2, 3, 5) and
has been shown to bind to B cells and increase the prolifer-
ation of B cells in combination with an anti–B cell receptor
antibody in vitro (2, 5). BAFF is a type II membrane pro-
tein and may act as either a membrane-bound or soluble
form, the latter being generated by proteolytic cleavage at a
furin consensus site (2, 5). Transgenic mice overexpressing
BAFF have a greatly elevated number of mature B cells and
an increased number of effector T cells in their spleen and
mesenteric lymph nodes (6). These mice display autoim-
mune-like manifestations including high levels of rheuma-
toid factors, circulating immune complexes, anti-DNA
autoantibodies, and Ig deposition in the kidney (6). How-
ever, splenic B cells from transgenic or control mice were
found to proliferate at the same rate (6), suggesting that
BAFF, in addition to its ability to costimulate B cell prolif-
eration in vitro, may have alternative functions.
B cell maturation antigen (BCMA) was first identified as
part of a translocation event in a malignant T cell lym-
phoma patient (7). Characterization of human BCMA
identified it as a type I membrane protein primarily ex-
pressed in immune organs and mature B cell lines (7, 8).
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BCMA protein was localized to the Golgi apparatus in the
U266 plasmacytoma cell line, which expresses high levels
of BCMA (9). Subsequent identification of the mouse
BCMA gene and further motif analysis led to the predic-
tion that BCMA is a member of the TNF receptor super-
family (10).
Here, we show that BAFF is capable of interacting with
the orphan TNF receptor, BCMA. We characterize the
BAFF–BCMA interaction and show that injection of solu-
ble BCMA-Ig fusion protein into mice leads to a dramatic
reduction in the total number of B cells in the peripheral
immune organs. This may be due to a B cell survival func-
tion of BAFF. Modulation of the peripheral B cell popula-
tion using BCMA-Ig treatment may be efficacious in treat-
ing B cell–mediated disorders.
 
Materials and Methods
 
Cells and Constructs.
 
Human embryonic 293 cells carrying
the EBNA-1 gene were cultured in DMEM
 
 
 
plus 10% FCS,
glutamine, pen-strep, and 250 
 
m
 
g/ml G418. Raji cells were ob-
tained from American Type Culture Collection and were cul-
tured as indicated. The human BCMA-hIgG1 (BCMA-Ig) ex-
pression vector was created using a murine 
 
k 
 
light chain signal
sequence, a PCR fragment generated to BCMA amino acids
1–48 (second Met), and a hIgG1 SalI 
 
1
 
 NotI fragment (11). The
fragments were cloned into pCEP4 (Invitrogen) derivative. A
COOH-terminal 6
 
3
 
His-tagged full-length human BCMA ex-
pression vector was generated by PCR. BCMA-Ig obtained by
transient transfection of 293E cells using Lipofectamine (Life
Technologies) was purified by protein A column chromatogra-
phy, and contained 
 
,
 
1 endotoxin U/mg of protein. The half-life
of this protein in mice is 
 
z
 
3.5 d. The control Ig, nonbinding
LFA3-Ig, was prepared from a Chinese hamster ovary (CHO)
cell line as described (12). Murine lymphotoxin (LT)
 
b
 
R-Ig (13)
and human LT
 
b
 
R-Ig (14) were made as described. Receptor-Ig
fusion proteins and Flag-tagged soluble ligands were constructed
and expressed as described using the following amino acid se-
quences: hTNF-
 
a
 
 (85–263), mBAFF (127–309), hBAFF (136–
285 or 83–285), human receptor activator of nuclear factor 
 
k
 
B
ligand (hRANKL [151–316]), hCD30L (63–234), hCD40L
(116–261), homologous to lymphotoxins, exhibits inducible ex-
pression, and competes with HSV glycoprotein D for herpesvirus
entry mediator (HVEM), a receptor expressed by T lymphocytes
(hLIGHT [89–240]), hTNFR2 (1–257), hTNF-related apopto-
sis-inducing ligand (hTRAIL)R2 (1–212), hCD30 (1–380),
hCD40 (1–193), hHVEM (1–200), and mRANK (1–200) (2,
15). Unless indicated, BAFF in 15-fold concentrated serum-free
Optimem medium (Life Technologies) was used (2).
 
Anti-BCMA Antibodies.
 
Rabbit anti-hBCMA antibody, Rb
1593, was generated against purified hBCMA-Ig. Affinity-puri-
fied anti-BCMA antibodies and control affinity-purified anti–
glutathione 
 
S
 
-transferase (GST) antibodies originating from the
same rabbit were used for the U266 cells and tonsillar B cell
staining. These antibodies have been described (9).
 
BIAcore Analysis.
 
All experiments were performed at 25
 
8
 
C
with a 10 
 
m
 
l/min flow rate using a BIAcore 2000™. HBS
buffer (10 mM Hepes, 150 mM NaCl, 0.005% P20 surfactant,
pH 7.4) was used both as the running buffer and as the sample
diluent. The CM5 chip (BIAcore) surface was first activated with
 
N
 
-hydroxysuccinimide/N-ethyl-N9-(3-diethylaminopropyl)-carbo-
 
diimide hydrochloride. 25 
 
m
 
l of BCMA-Ig or hLT
 
b
 
R-Ig was
diluted to 30 
 
m
 
g/ml in 10 mM acetic acid (pH 5), then injected.
The unreacted groups of the chip’s dextran matrix were blocked
twice with ethanolamine-HCl (pH 8.5). For the experiment,
100 
 
m
 
l of Flag-hBAFF, Flag-mBAFF, or hLT
 
a
 
1
 
b
 
2
 
 at 30 
 
m
 
g/ml
in diluent buffer were injected over the surface of the chip. The
surface was regenerated between experiments by washing with
1 mM formic acid.
 
BCMA-Ig Blocking of BAFF Binding to Raji Cells.
 
Flag-tagged
human BAFF at 200 ng/ml was pre-incubated for 30 min on
ice in FACS
 
®
 
 buffer (PBS, 10% FCS, 0.05% azide) with either
hBCMA-Ig or hLT
 
b
 
R-Ig at twofold dilutions ranging from 20
 
m
 
g/ml to 39 ng/ml, or with BAFF alone. The mixture was added
to Raji cells for 30 min on ice. Bound BAFF was detected using 5
 
m
 
g/ml anti-Flag antibody M2 (Sigma-Aldrich) followed by PE-
conjugated donkey anti–mouse IgG (Jackson ImmunoResearch
Laboratories). The samples were read using a FACSCalibur™
flow cytometer (Becton Dickinson).
 
Anti-BCMA Antibody and BAFF Binding to Full-length BCMA-
transfected Cells.
 
293E cells were transfected with either vector
alone or His-tagged full-length BCMA and a green fluorescent
protein transfection control plasmid (gift of N. Horikoshi, Beth
Israel Deaconess Medical Center, Boston, MA) using Lipo-
fectamine 2000. After 48 h, the cells were detached in PBS con-
taining 5 mM EDTA, washed, and stained for 30 min on ice with
anti-hBCMA Rb 1593 (1:1,000) or preimmune sera (1:500) fol-
lowed by PE-conjugated donkey anti–rabbit Ig (1:100; Jackson
ImmunoResearch Laboratories). Alternatively, cells were stained
plus or minus Flag-BAFF (2 
 
m
 
g/ml) and detected using M2 as
described above.
 
BAFF and Anti-BCMA Antibody Binding to Human Tonsillar B
Cells.
 
Human mononuclear cells were obtained from palatine
tonsils by gentle dissociation with forceps. T cells were removed
by one cycle of rosette formation and further depleted with anti-
CD2 magnetic beads (Dynabeads M-450; Dynal [16]). The re-
maining B cell populations were 93
 
 6 
 
4% CD19
 
1
 
, 59
 
 6 
 
6%
IgD
 
1
 
, 56
 
 6 
 
5% IgM
 
1
 
, 81
 
 6 
 
16% CD44
 
1
 
, 21
 
 6 
 
6% CD38
 
1
 
, 42
 
 6
 
1% CD95
 
1
 
,
 
 
 
and
 
 
 
# 
 
1% CD14
 
1
 
, CD3
 
1
 
, and DRC1
 
1
 
 
 
cells. Cells
were preincubated with 10% human AB serum and stained plus
or minus Flag-BAFF (amino acids 83–285) at 1 
 
m
 
g/ml followed
by M2 (7.5 
 
m
 
g/ml) and PE-conjugated goat anti–mouse IgG
(Immunotech). Anti-BCMA staining was done using 20 
 
m
 
g/ml
antibody and FITC-conjugated goat anti–rabbit IgG (Immuno-
tech).
 
BCMA-Ig Injection into Mice.
 
6-wk-old female BALB/c mice
(four per group; The Jackson Laboratory) received intraperitoneal
injections of either 400 
 
m
 
g of BCMA-Ig or 400 
 
m
 
g of LFA3-Ig
(control Ig) on days 1, 4, 8, and 11. On day 19, the mice were
killed. Blood was collected via cardiac puncture into tubes con-
taining EDTA. Single cell suspensions were prepared from
spleens and mesenteric lymph nodes, and RBCs were lysed in a
hypotonic buffer. Flow cytometry was performed using PE-,
FITC-, or CyChrome-conjugated anti-CD45R/B220 (B cells)
and anti-CD4, anti-CD8 (T cells), or anti-Gr1/anti–Mac-1 (neu-
trophils and macrophages). All antibodies were purchased from
BD PharMingen. In brief, Fc receptors were blocked with 10
 
m
 
g/ml FcBlock (BD PharMingen) for 15 min on ice followed by
addition of the conjugated mAbs, and were incubated on ice for
30 min. Cells were washed twice, suspended in 0.5% paraformal-
dehyde, and analyzed by flow cytometry.
 
B Cell Survival Assay.
 
Mouse spleens were collected under
sterile conditions and homogenized in RPMI medium plus 10%
FCS using SuperFrost glass slides (Menzel-Glaser). Cells were fil- 
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tered through a 70-
 
m
 
m nylon cell strainer (Falcon) before centrif-
ugation at 1,000 rpm (300 
 
g
 
) for 5 min. The pellet was resus-
pended in 2 ml/spleen RBC lysis solution and incubated on ice
for 5 min. The remaining white blood cells were collected by
centrifugation and resuspended in media. Splenocytes were incu-
bated at a concentration of 3 
 
3
 
 10
 
6
 
 cells/ml in media for 72 h.
The splenocytes were either untreated or were in the presence of
2 
 
m
 
g/ml human Flag-BAFF (amino acids 83–285) alone or with
20 
 
m
 
g/ml BCMA-Ig or 20 
 
m
 
g/ml murine LT
 
b
 
R-Ig. The per-
cent live cells remaining was determined using the annexin V–FITC
Apoptosis Detection Kit 1 (BD PharMingen). Cells were washed
twice and then analyzed using a FACSCalibur™ machine (Bec-
ton Dickinson).
 
Results and Discussion
 
BAFF Interacts with Soluble BCMA.
 
TNF receptor fam-
ily members are generally type I proteins with a leader se-
quence and a cysteine-rich extracellular domain. The ex-
tracellular domains are organized as a series of alternating A
and B modules, which are stabilized by internal disulfide
bridges (17). A single C module, not involved in ligand
binding, is found in the fourth cysteine repeat of TNFRI
(17). In a previous study, BAFF failed to bind to 16 mem-
bers of the TNF receptor family (2). Subsequently, an addi-
tional candidate receptor for BAFF was identified, termed
B cell maturation antigen (10). BCMA appears to be dis-
tantly related to the TNF receptor family, because it is de-
void of a signal sequence and contains a single A and one C
module instead of multiple A and B modules (10). How-
ever, the expression pattern of this atypical receptor in ma-
ture B cells prompted us to examine its interaction with
BAFF (8, 9). To this end, the extracellular domain of hu-
man BCMA was expressed as a human IgG1 fusion protein
and was targeted to the secretory pathway with an added
signal peptide. BCMA-hIgG1 (BCMA-Ig) fusion protein
immunoprecipitated both recombinant human and murine
BAFF very efficiently, but not five other TNF ligands
(CD40L, RANKL, CD30L, LIGHT, and TNF-
 
a
 
) which,
however, interacted with their respective receptors in con-
trol immunoprecipitations (Fig. 1 A). When the interaction
was tested in another format using surface plasmon reso-
nance (BIAcore) analysis, similar results were obtained, and
both murine and human BAFF exhibited a significant affin-
ity for human BCMA-Ig but not for LT
 
b
 
R-Ig (Fig. 1 B).
In addition, BCMA-Ig interacted with membrane-bound
BAFF expressed in 293 cells (Fig. 1 C), and in a dose-
Figure 1. The extracellular
domain of BCMA interacts with
BAFF. (A) Human BCMA-Ig
and various control TNFR-Ig
molecules were mixed with
Flag-tagged TNF ligands, im-
munoprecipitated (IP) with pro-
tein A Sepharose, and analyzed
by Western blot (WB). Recep-
tor-Ig is revealed with anti–human
IgG (top), and coimmunopre-
cipitating ligands are detected
using anti-Flag M2 antibody
(bottom).  a, anti-. (B) Interac-
tion of BAFF with BCMA as-
sayed by surface plasmon reso-
nance (BIAcore). (C) BCMA-Ig
binds stable 293 cell line express-
ing surface full-length BAFF.
The wild-type 293 cells or a sta-
ble cell line expressing BAFF
(reference 2) were stained with
media containing similar
amounts of BCMA-Ig, TNFR2-
Ig, TRAILR2-Ig, or control
media using PE-conjugated anti-
hIgG1 (left and middle). The
presence of surface BAFF was
detected using an anti-hBAFF
rat mAb, 43.9 (reference 2;
right). (D) BCMA-Ig blocks
BAFF binding to Raji cells. Var-
ious concentrations of either
BCMA-Ig or LTbR-Ig were
preincubated with Flag-BAFF,
then added to Raji cells. BAFF
binding was detected with the
anti-Flag M2 antibody and ana-
lyzed by flow cytometry. 
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dependent manner specifically blocked the interaction of
BAFF with Raji B cells (Fig. 1 D). Thus, the short extra-
cellular domain of BCMA is sufficient for high-affinity
binding to BAFF, and there is no species barrier for the
murine BAFF–human BCMA interaction. The BAFF–
BCMA interaction is presently unique in the family, as it
involves only two modules, one predicted to be of the C
type. In the two cases where the crystal structure of the tri-
meric ligand–receptor complex is known (LT
 
a
 
–TNFR1
and TRAIL–TRAILR2), the contacts involved in the in-
teraction have been shown to involve one B and two A
modules (18–20).
 
Cell Surface Expression of BCMA.
 
Cell surface expres-
sion of BCMA is a likely prerequisite for BAFF binding.
Indeed, most 293E cells transfected with a construct en-
coding full-length BCMA with no added signal peptide
were positive for surface staining with anti-BCMA anti-
Figure 2. Cell surface expression of BCMA in transfected and primary
cells. (A) 293E cells were cotransfected with expression vectors for green
fluorescent protein (GFP) and full-length human BCMA or a control
plasmid. Surface expression of BCMA was detected with either an anti-
BCMA antibody (top) or Flag-BAFF (bottom). (B) Human tonsillar B
cells and the U266 plasmocytic cell line were stained with either anti-
BCMA, control rabbit antibody, or Flag-BAFF, and were analyzed by
flow cytometry.
Figure 3. Administration of BCMA-Ig reduces the peripheral B cell
population. Adult Balb/c mice were treated with four intraperitoneal in-
jections of BCMA-Ig or control Ig over a period of 11 d. At day 19,
splenic B2201 B cells, CD41 and CD81 T cells, and Gr11 and Mac-11
populations were analyzed by flow cytometry. A representative mouse
from each group is shown. 
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bodies and to a lesser extent with Flag-BAFF, whereas un-
transfected cells or cells transfected with a control plasmid
were not (Fig. 2 A). We also found that tonsillar B cells
were stained with both anti-BCMA and Flag-BAFF (Fig. 2
B), suggesting that surface expression of BCMA also occurs
in primary cells and is not an artifact of overexpression.
Therefore, in the absence of a signal sequence, the trans-
membrane domain of BCMA must dictate the topology of
membrane insertion for correct expression at the cell sur-
face. In a previous study, BCMA was located exclusively in
the Golgi apparatus of the plasmocytic cell line U266, and
not at the cell surface, despite the fact that these cells ex-
press high levels of the protein (9). Consistent with this ob-
servation, we find that U266 cells were not stained with ei-
ther the anti-BCMA antibody or Flag-BAFF (Fig. 2 B).
These results suggest that surface expression of BCMA may
be a tightly controlled, cell type–dependent mechanism.
Intracellular pools of the cytotoxic receptor Fas can be mo-
bilized for surface expression in response to p53 activation,
a mechanism that probably contributes to the elimination
of damaged cells (21). It is an intriguing possibility that cells
may release intracellular BCMA at the cell surface in re-
sponse to specific stimuli, and therefore become sensitive to
BAFF effects.
B Cell Reduction with BCMA-Ig Treatment. Because BIA-
core studies revealed that murine BAFF was able to effec-
tively bind human BCMA-Ig, we used the fusion protein
to examine the effect of disrupting the BAFF signal in nor-
mal mice. Four administrations of BCMA-Ig at intervals of
3–4 d dramatically reduced the total number of B cells in
the blood and peripheral lymphoid organs examined. The
B2201 B cell population in the spleen of BCMA-Ig–
treated animals was reduced by 50% compared with the
control Ig–treated mice. In contrast, populations of neutro-
Table I. The Total Number of Splenocytes and Splenic Subpopulations Examined after Treatment with BCMA-Ig
Mouse Total cells B cells CD41 T cells CD81 T cells Neutrophils Mac-11 cells
BCMA-Ig treated
B1 58.5 21.5 16.9 7.5 4.6 12.1
B2 66.0 24.4 19.5 8.3 3.9 12.4
B3 46.5 11.7 14.9 8.3 3.4 10.0
B4 36.0 11.0 12.7 6.5 2.2 6.9
Mean 6 SD 51.8 6 11.4 17.2 6 5.9 16.0 6 2.5 7.7 6 0.7 3.5 6 0.9 10.4 6 2.2
Controls
A1 73.5 40.4 17.9 6.2 4.1 13.3
A2 72.8 39.1 16.1 6.6 4.5 13.7
A3 81.8 42.9 20.4 9.2 3.8 13.2
A4 43.5 21.6 10.4 4.2 3.2 9.0
Mean 6 SD 67.9 6 14.5 36.0 6 8.4 16.2 6 3.7 6.6 6 1.8 3.9 6 0.5 12.3 6 1.9
P values P . 0.1 P 5 0.02 P . 0.1 P . 0.1 P . 0.1 P . 0.1
The number of cells (3106) from individual mice in each group is shown. P values were determined by Student’s t test.
Figure 4. BAFF promotes the survival of splenocytes in vitro. (A) For-
ward (FSC) and side scatter (SSC) profiles of murine splenocytes in cul-
ture after 72 h in the presence or absence of BAFF. The R2 gate contains
live cells (annexin V and propidium iodide negative). (B) Percentage of
R2 cells surviving. BAFF concentration was 2 mg/ml, and fusion proteins
were added at 10 mg/ml. This is a representative experiment of the assay
done z10 times.134 BAFF Binds BCMA and Is Important for Maintaining B Cell Population
phils, macrophages, CD41 T cells, and CD81 T cells were
not significantly affected by BCMA-Ig (Fig. 3 and Table I).
The decrease in absolute B cell number corresponded to
the decrease in absolute total cell number (Table I), indi-
cating that the reduction in the B cell population was not
due to a concordant increase in other cell types. Therefore,
the BCMA-Ig treatment specifically affected B cells. Simi-
lar results were observed in the blood and mesenteric
lymph nodes, where approximately half of the B2201 B
cells were lost (data not shown). As B cells do not express
BAFF (2, 5), and because human BCMA-Ig does not bind
to mouse splenic B cells (data not shown), we can exclude
antibody-dependent cell-mediated cytotoxicity as the
mechanism of action. Although BAFF is thought to be pri-
marily secreted, staining of splenocytes using BCMA-Ig re-
vealed that BAFF is found on the surface of Mac-11 cells
(data not shown).
BCMA-Ig treatment given over the course of 11 d may
reduce the peripheral B cell pool by inhibiting production
or release of immature B cells from the bone marrow, by
blocking maturation of immature B cells, or by sequester-
ing a factor required for B cell survival. At least 20 3 106
immature B cells are generated in the bone marrow each
day, and from this population an estimated 2–3 3 106 B
cells enter the periphery (22). It has been shown that main-
tenance of the peripheral B cell pool requires a minimum
continuous input of newly formed cells (23), but that less
than half of the B cells that reach the spleen progress to the
mature phenotype (24). Although the percentage of long-
lived and short-lived B cells in the periphery is controver-
sial (22), the average half-life of the B2201 cells in the
spleen is 4.3 wk, indicating that the majority of the B cells
are long-lived mature cells (24). As we see a 50% decrease
in the total B cell population in the periphery, we may be
affecting the repopulation of the spleen with mature B cells
or the survival of the existing mature B cells. One possible
mechanism for sustaining B cell survival is to upregulate the
antiapoptotic protein Bcl-2. Interestingly, elevated levels of
Bcl-2 have been reported in the PBL B cells isolated from
BAFF transgenic mice (6). To delineate the peripheral B
cell subpopulations modulated by BCMA-Ig, the mecha-
nism of action, as well as any potential effect on B cell de-
velopment in the bone marrow, a more comprehensive
study is in progress.
B Cell Survival with BAFF. The in vivo analysis, taken
together with the finding that BAFF transgenic mice have
an increased number of mature B cells and Bcl-2 expres-
sion, indicates that BAFF may promote B cell survival. We
next examined the direct effect of BAFF on the survival of
murine splenocytes in vitro. Splenocytes were cultured for
72 h in the presence or absence of BAFF and either
BCMA-Ig or LTbR-Ig (Fig. 4). BAFF alone caused an in-
crease in the percentage of cells that survived, and this ef-
fect was blocked with BCMA-Ig. The increase in cell
numbers was not due to the increase in proliferation, as this
has not been observed in the absence of B cell receptor
stimulation (2, 3). The majority of the surviving cells,
z80%, were B2201 B cells, although a small percentage of
T cells also survived (data not shown). Thus, BAFF is capa-
ble of directly enhancing B cell survival.
In conclusion, we have identified BCMA as a receptor
for BAFF. Soluble BCMA antagonizes BAFF action and
leads to a rapid, significant B cell decline in vivo, suggesting
that BAFF is necessary for homeostasis of the peripheral B
cell pool. The increase in mature B cell numbers observed
in the BAFF transgenic mice and the ability of BAFF to
sustain B cells in vitro indicate that BAFF functions as a
survival factor. Modulation of the peripheral B cell popula-
tion using soluble BCMA may have applications in treating
B cell–mediated autoimmune diseases, plasma cell disor-
ders, and B cell cancers. A very recent report has demon-
strated that blocking the BAFF pathway in two models of
SLE using a soluble version of another receptor for BAFF,
transmembrane activator and calcium modulator and cyclo-
philin ligand (CAML) interactor (TACI)-Ig, eliminates
proteinurea and prolongs the life span of the mice (25).
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